Healthcare Professional – AML-ALL US Focus Meeting 2023

AML-ALL US Focus Meeting 2023

Course Information

Course Instructor

Author

Register now!

FREE

Your personal data will be used to process your registration, support your experience on this website, and for other purposes described in our Privacy Policy.

Section I

Ryan Fitzpatrick

Session I

The genetic landscape and molecular diagnostics in AML – Joe Khoury, University of Nebraska Medical Center

Optimizing frontline therapy for FLT3 mutated AML patients eligible for Intensive Chemotherapy – Harry Erba, Duke Blood Cancer Center, Durham

Genomic strategies to guide the choice of intensive treatment strategies in non-FLT3m AML – Amir Fathi, Massachusetts General Hospital, Boston

Diagnostic and Molecular Work-up of Newly Diagnosed AML – The Pathologists’ Perspective – Sanam Loghavi, MD Anderson Cancer Center Houston, Texas

Panel Discussion

Session II

Updates on the management and mechanisns of resistance in R/R FT3 mutated AML – Alexander E. Perl, Hospital of University of Pennsylvania, Philadelphia PA

How do I assess for MRD in clinical practice and how do I use MRD to guide post remission therapy – Farhad Ravandi, MD Anderson Cancer Center Houston, Texas

How do I use IDH inhibitors in the frontline and R/R Setting: Single agent versus combinations – Courtney DiNardo, MD Anderson Cancer Center Houston, Texas

Current status and future directions with menin inhibitors in AML – Eytan Stein, Memorial Sloan Kettering Cancer Center, New York

Panel Discussion

Session III

The case for upfront triplets – Naval Daver, MD Anderson Cancer Center, Houston, Texas

The case for sequential triplets – Jessica Altman, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois

Panel Discussion

Developing immune and cellular therapies in AML – Yasmin Abaza, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois

How do I Manage AML Patients Receiving HMA/venetoclax based therapies; A focus on practical approaches – Brian Jonas, UC Davis Health, Sacramento, CA

Panel Discussion

Session IV

Mechanisms of resistance and novel combinations with venetoclax based therapies in AML – Marina Konopleva, MD Anderson Cancer Center Houston, Texas

Optimizing maintenance therapy in AML post-consolidation and post-transplant – Tapan Kadia, MD Anderson Cancer Center, Houston, Texas

Immune based approaches in AML/MDS – Hetty Carraway, Cleveland Clinic, Ohio

Optimizing SCT approaches including conditioning and maintenance in AML – Andrew Artz, City of Hope, Chicago, Illinois

Panel Discussion

Astellas Sponsored Expert Discussion

Session V

Incorperating targeted therapies: Menin, FLT3, IDH and others in pediatric populations – Branko Cuglievan, MD Anderson Cancer Center, Houston, Texas

The genetic landscape and molecular diagnostics in ALL – Charles Mullighan, St. Jude Children’s Research Hospital, Memphis, Tennessee

Walking away from chemotherapy – Elias Jabbour, MD Anderson Cancer Center, Houston, Texas

When to transplant in ALL – Mark Litzow, Mayo Clinic Comprehensive Cancer Center

Panel Discussion

Session VI

Debate 1: Integration of immunotherapy into frontline therapy – Inotuzumab Ryan Cassaday, Fred Hutchinson Cancer Center, Seattle, Washington

Debate 1: Integration of immunotherapy into frontline therapy – Blinatumomab Anjali Advani, Cleveland Clinic, Ohio

Debate 1: Integration of immunotherapy into frontline therapy – Discussion

Debate 1: Integration of immunotherapy into frontline therapy – How to approach Ph-like ALL Marina Konopleva, MD Anderson Cancer Center, Houston, Texas

Debate 1: Integration of immunotherapy into frontline therapy – How to tailor therapy according to MRD: when to escalate and when to de-escalate Aaron Logan, University of California, San Francisco

Debate 1: Integration of immunotherapy into frontline therapy – Panel Discussion

Session VII

Debate 2: Relapsed-Refractory disease – Immunotherapy in ALL Elias Jabbour, MD Anderson Cancer Center, Houston, Texas

Debate 2: Relapsed-Refractory disease – CAR T-cells in ALL Bijal Shah, Moffitt Cancer Center, Tampa, Florida

Debate 2: Relapsed-Refractory disease – Discussion

Debate 2: Relapsed-Refractory disease – BCL2 inhibitors in ALL Marlise Luskin, Dana-Farber Cancer Institute, Boston, Massachusetts

Debate 2: Relapsed-Refractory disease – How to optimize pediatric regimens and the use of asparaginase Wendy Stock, The University of Chicago

Debate 2: Relapsed-Refractory disease – Panel Discussion

Session VIII

Novel agents and pathways in T-ALL and ETP-ALL – Nitin Jain, MD Anderson Cancer Center, Houston, Texas

Novel CAR T approaches – Regina Myers, Childrens Hospital of Philadelphia

Older adults with ALL – Shira N Dinner, Northwestern Medicine, Feinberg School of Medicine, Chicago, IL

Future of ALL therapies – Hagop Kantarjian, MD Anderson Cancer Center, Houston, Texas

Panel Discussion

Estancia Hotel, La Jolla, California